Intabio Inc had been developing an analytical platform - designated Blaze⢠- designed to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing. The Blaze system enables direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins, offering a many-fold higher throughput over traditional methods. This feature has ben judged likely to enable biopharma companies to meet the accelerated timelines required for breakthrough therapy applications, reducing the risk of costly production delays and failures - potentially improving product quality, reducing manufacturing cost, and increasing speed to market, Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.
